Office of the Secretary; Notice of Meeting, 73062 [2020-25190]

Download as PDF 73062 Federal Register / Vol. 85, No. 221 / Monday, November 16, 2020 / Notices minutes per person to ensure time is allotted for all those wishing to speak. Individuals are also welcome to submit written comments in advance. Written comments should not exceed three pages in length. Individuals submitting comments should email their written comments or their request to provide a comment during the meeting to nvac@ hhs.gov at least five business days prior to the meeting. Dated: October 27, 2020. Ann Aikin, Acting Designated Federal Official, Office of the Assistant Secretary for Health. [FR Doc. 2020–25243 Filed 11–13–20; 8:45 am] BILLING CODE 4150–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting jbell on DSKJLSW7X2PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group; Acquired Immunodeficiency Syndrome Research Review Committee Acquired Immunodeficiency Syndrome Research Review Committee (AIDS). Date: December 9–10, 2020. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G21, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Robert C. Unfer, PhD., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G21, Rockville, MD 20852, (240) 669–5035, robert.unfer@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, VerDate Sep<11>2014 20:13 Nov 13, 2020 Jkt 253001 Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: November 9, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. Dated: November 9, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–25190 Filed 11–13–20; 8:45 am] BILLING CODE 4140–01–P [FR Doc. 2020–25185 Filed 11–13–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Secretary; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Muscular Dystrophy Coordinating Committee (MDCC). The meeting will be open to the public. Individuals who plan to participate and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Muscular Dystrophy Coordinating Committee. Date: December 16, 2020. Time: 1:00 p.m. to 4:00 p.m. Agenda: The purpose of this meeting is to bring together committee members, representing government agencies, patient advocacy groups, other voluntary health organizations, and patients and their families to update one another on progress relevant to the Action Plan for the Muscular Dystrophies and to coordinate activities and discuss gaps and opportunities leading to better understanding of the muscular dystrophies, advances in treatments, and improvements in patients’ and their families’ lives. The agenda for this meeting is available on the MDCC website: https://www.mdcc.nih.gov/ Meetings_Events/december-16-2020. Registration: To register, please go to: https://roseliassociates.zoomgov.com/ webinar/register/WN_ztgxOEmQPKtTSwCXWyk1w. Webcast Live: https://videocast.nih.gov/. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Bethesda, MD 20892, (Virtual Meeting). Contact Person: Glen Nuckolls, Ph.D., Program Director, National Institute of Neurological, Disorders and Stroke (NINDS), NIH, 6001 Executive Blvd., Rm 2203, Bethesda, MD 20892, 301–496–5876, MDCC@ nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. More information can be found on the Muscular Dystrophy Coordinating Committee home page: https://mdcc.nih.gov/. PO 00000 Frm 00046 Fmt 4703 Sfmt 9990 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed). Date: December 8–10, 2020. Time: 8:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F43, Rockville, MD 20892, (Virtual Meeting). Contact Person: Kelly Y. Poe, Ph.D., Deputy Director, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F43, Bethesda, MD 20892–9834, (240) 669– 5036, poeky@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: November 9, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–25187 Filed 11–13–20; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\16NON1.SGM 16NON1

Agencies

[Federal Register Volume 85, Number 221 (Monday, November 16, 2020)]
[Notices]
[Page 73062]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25190]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Secretary; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Muscular Dystrophy 
Coordinating Committee (MDCC).
    The meeting will be open to the public. Individuals who plan to 
participate and need special assistance, such as sign language 
interpretation or other reasonable accommodations, should notify the 
Contact Person listed below in advance of the meeting.

    Name of Committee: Muscular Dystrophy Coordinating Committee.
    Date: December 16, 2020.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: The purpose of this meeting is to bring together 
committee members, representing government agencies, patient 
advocacy groups, other voluntary health organizations, and patients 
and their families to update one another on progress relevant to the 
Action Plan for the Muscular Dystrophies and to coordinate 
activities and discuss gaps and opportunities leading to better 
understanding of the muscular dystrophies, advances in treatments, 
and improvements in patients' and their families' lives. The agenda 
for this meeting is available on the MDCC website: https://www.mdcc.nih.gov/Meetings_Events/december-16-2020.
    Registration: To register, please go to: https://roseliassociates.zoomgov.com/webinar/register/WN_ztgxOE-mQPKtTSwCXWyk1w.
    Webcast Live: https://videocast.nih.gov/.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Blvd., Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Glen Nuckolls, Ph.D., Program Director, National 
Institute of Neurological, Disorders and Stroke (NINDS), NIH, 6001 
Executive Blvd., Rm 2203, Bethesda, MD 20892, 301-496-5876, 
[email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    More information can be found on the Muscular Dystrophy 
Coordinating Committee home page: https://mdcc.nih.gov/.

    Dated: November 9, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-25190 Filed 11-13-20; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.